Structural refinement and prediction of potential CCR2 antagonists through validated multi-QSAR modeling studies

Area of Science:

• Medicinal Chemistry
• Immunology
• Pharmacology

Background:

• Chemokines modulate immune responses and are implicated in inflammatory conditions.
• Monocyte chemoattractant protein-1 and chemokine receptor 2 (CCR2) interaction is linked to atherosclerosis, obesity, insulin resistance, and other inflammatory diseases.
• Development of selective CCR2 antagonists is vital despite clinical trial failures.

Purpose of the Study:

• To perform multi-QSAR modeling on 83 CCR2 antagonists from Johnson & Johnson Pharmaceuticals.
• To elucidate structural and pharmacophoric requirements for potent CCR2 antagonist design.
• To propose novel molecules with potentially enhanced CCR2 inhibitory activity.

Main Methods:

• Utilized robust, validated multi-QSAR modeling studies.
• Analyzed 83 CCR2 antagonists to identify structure-activity relationships.
• Correlated and validated findings across different modeling approaches.

Main Results:

• Developed statistically reliable and validated QSAR models for CCR2 antagonists.
• Identified critical structural and pharmacophoric features influencing CCR2 antagonist potency.
• Observations from modeling studies were consistent and mutually validating.

Conclusions:

• QSAR modeling provides valuable insights into the design of potent CCR2 antagonists.
• The identified structural and pharmacophoric requirements can guide future drug discovery efforts.
• Proposed novel molecular structures with potential for improved CCR2 antagonism.